Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
letrozole + nintedanib
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Letrozole + nintedanib is a combination therapy being investigated for breast cancer treatment. Letrozole is an aromatase inhibitor that reduces estrogen production, while nintedanib is a multikinase inhibitor targeting FGFR1 and other pathways. This combination aims to provide dual inhibition of hormone-dependent growth pathways and angiogenesis in hormone-receptor positive breast cancer.
02
Targets
CYP19A1 (Aromatase)FGFR1 (Fibroblast growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on letrozole + nintedanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on letrozole + nintedanib.